WF 3681
Latest Information Update: 23 Jun 1998
Price :
$50 *
At a glance
- Originator Fujisawa
- Class Antihyperglycaemics
- Mechanism of Action Aldehyde reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications
Most Recent Events
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 29 Aug 1996 New profile
- 29 Aug 1996 Discontinued-Preclinical for Diabetic complications in Japan (Unknown route)